The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Pulse Biosciences, Inc. (NASDAQ: PLSE) who purchased shares between January 12, 2021 and February 7, 2022. The action, which was filed in the United States District Court for the Northern District of California, alleges that the Company violated federal securities laws.
In particular, the Pulse lawsuit alleges that (1) the investigational device exemption study evaluating the use of the Company’s CellFX System to treat sebaceous hyperplasia lesions failed to meet its primary endpoints; (2) as a result, there was a substantial risk that the U.S. Food and Drug Administration would reject Pulse’s 510(k) submission seeking to expand the label for the CellFX System to treat sebaceous hyperplasia lesions; and (3) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Shareholders have until April 18, 2022 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
To learn more and keep informed, complete this form >